Raul RAMOS PUPO
Immunologist MD, PhD student
Biomedical Research Institute, Hasselt University
Hasselt, Belgium
MD, specializing in Immunology. Over ten years of clinical, research, and teaching experience. PhD at UHasselt evaluating a COVID-19 mucosal vaccine formulation
About
Raul Ramos Pupo is a 36-year-old Medical Doctor specializing in Immunology with over ten years of clinical, research, and teaching experience. In 2013, he graduated as MD with outstanding academic results and, in 2017, became a Fundamental and Clinical Immunology Specialist at Havana Medical University. In 2019, he started a PhD in Biomedical Sciences under the supervision of Prof. dr. Piet Stinissen at Hasselt University, conducting a preclinical evaluation of a COVID-19 mucosal vaccine formulation adjuvanted with Bacillus subtilis spores. He has published in reputable peer-reviewed scientific journals and attended key international scientific meetings. As a grounded and solution-oriented scientist, he loves bringing big ideas to life while maintaining focus, strategic orientation, and the ability to lead and inspire others.
My organisation
We are the Biomedical Research Institute at Hasselt University. Our multidisciplinary team of researchers is committed to advancing knowledge in the biomedical field through cutting-edge research and innovative collaborations. With state-of-the-art facilities and a focus on translating research into real-world applications, we aim to make meaningful contributions to healthcare and improve quality of life. Join us in our mission to push the boundaries of biomedical science and make a difference in the world.
Skills
- Immunoprophylaxis
- Diagnosis & Treatment
- Animal Models
- Laboratory Skills
- Advanced Technology
- Data Analysis
- project management
- Creative thinking
Interests
- Scientific innovations
- High education
- Entrepreneurship
- Sports
Speaker sessions (1)
Tuesday, 17 September 2024
14:50 - 15:05
A COVID-19 mucosal vaccine formulation adjuvanted with Bacillus subtilis spores - University of Hasselt
The SARS-CoV-2 receptor-binding domain (RBD) coadministered with Bacillus subtilis spores through the nasal route induces robust humoral and cellular, both mucosal and systemic immune responses in mice.